PX1 Research provides high-purity MIF-1 (Melanocyte-Inhibiting Factor 1) peptide engineered specifically for rigorous laboratory and in vitro experimental applications. Every lot undergoes extensive analytical validation—including RP-HPLC purity assessment, mass spectrometry, and endotoxin quantification—to deliver consistent, reproducible data for primary research facilities.
PX1 Research provides high-purity MIF-1 (Melanocyte-Inhibiting Factor 1) peptide engineered specifically for rigorous laboratory and in vitro experimental applications. Every lot undergoes extensive analytical validation—including RP-HPLC purity assessment, mass spectrometry, and endotoxin quantification—to deliver consistent, reproducible data for primary research facilities.
Investigators seeking to buy MIF-1 peptide (Melanocyte-Inhibiting Factor 1) require verified, high-purity (>98%) reference material accompanied by full analytical documentation. PX1 Research supplies synthetic MIF-1 tripeptide manufactured in USA-based, GMP-compliant facilities, specifically formulated for in vitro assays and preclinical neurochemical models. Each batch undergoes rigorous testing to guarantee sequence accuracy, lot-to-lot consistency, and freedom from residual contaminants.
When you buy MIF-1 peptide through PX1 Research, every order includes a lot-specific Certificate of Analysis (COA) detailing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) purity data, Electrospray Ionization Mass Spectrometry (ESI-MS) molecular mass confirmation, and Limulus Amebocyte Lysate (LAL) endotoxin testing. Orders placed before cut-off times ship same-day from our California and Arizona fulfillment centers to maintain cold-chain handling and structural stability.
MIF-1, also known structurally as Prolyl-Leucyl-Glycinamide (PLG) or Melanostatin, is an endogenous brain tripeptide with the chemical sequence H-Pro-Leu-Gly-NH2. With a molecular weight of 284.36 Da, MIF-1 was originally isolated as a cleavage product derived from the C-terminal tail of the neurohypophyseal hormone oxytocin. Despite its historical name, subsequent neurochemical research demonstrated that its primary physiological and pharmacological actions extend far beyond pituitary melanocyte modulation.
In the central nervous system, MIF-1 functions as a potent modulator of neurotransmitter receptor complexes. Because of its concise tripeptide structure, MIF-1 serves as a fundamental scaffold in chemical biology for studying neuropeptide folding, enzyme cleavage resistance, and allosteric receptor binding dynamics. Facilities evaluating compounds across our catalog of research peptides frequently utilize MIF-1 as a baseline reference for small endogenous peptide signaling.
The primary focus of preclinical literature regarding MIF-1 centers on its capacity to act as a positive allosteric modulator (PAM) at dopamine D2 and D3 receptor sites. In vitro membrane binding assays indicate that MIF-1 does not directly compete with endogenous dopamine or classic agonists at the primary orthosteric binding site. Instead, it binds to a distinct allosteric domain on the G-protein coupled receptor (GPCR) complex, stabilizing high-affinity agonist conformations.
Radioperfusion and receptor-binding studies in striatal membrane preparations demonstrate that MIF-1 enhances dopamine binding affinity without altering total receptor density (Bmax). In rodent models evaluating movement dysregulation and basal ganglia function, administration of MIF-1 has been observed to potentiate dopaminergic signaling cascades while mitigating motor impairments induced by neurotoxins like MPTP or 6-OHDA. Researchers exploring dopamine receptor modulators study MIF-1 to elucidate non-competitive strategies for tuning central neurotransmission.
In addition to its dopaminergic activity, in vitro and animal models show that MIF-1 interacts with endogenous opioid systems. Preclinical investigations demonstrate that MIF-1 acts as an endogenous functional antagonist or modulator of mu-opioid signaling under specific physiological conditions. For example, rodent nociceptive assays show that central administration of MIF-1 attenuates morphine-induced analgesia and opioid-mediated tolerance responses without displaying intrinsic opiate toxicity.
Behavioral science models—including the forced swim test and tail suspension test in mice—indicate that MIF-1 exhibits potent, non-sedating antidepressant-like activity. Unlike traditional monoamine reuptake inhibitors, MIF-1 operates through distinct neuropeptide pathways that interact with the hypothalamic-pituitary-adrenal (HPA) axis. Literature detailed in our PX1 Research Library highlights how these dual dopaminergic-opioid interactions make MIF-1 a key compound for deciphering complex neurobehavioral phenotypes.
When mapping neuropeptide pathways, investigators frequently compare MIF-1 to structurally modified synthetic analogs and adjacent melanocortin signaling molecules. A notable comparison is Nemifitide (4-fluoro-L-prolyl derivative), a synthetic peptidomimetic designed to enhance enzymatic stability while retaining the core Pro-Leu-Gly pharmacological motif. While Nemifitide exhibits an extended half-life in serum assays, MIF-1 remains the benchmark wild-type peptide for fundamental receptor binding kinetics.
MIF-1 is also frequently contextualized alongside broader melanocortin-related signaling peptides, such as PT-141 (Bremelanotide) and Melanotan II. However, unlike PT-141 and Melanotan II, which act as direct agonists at melanocortin receptors (MC3R, MC4R, MC1R), MIF-1 operates largely independently of primary melanocortin GPCRs, exerting its effects via dopaminergic and opioid allosterism. Researchers investigating neuropeptide signaling cascades often run parallel assays comparing these distinct classes to dissect upstream versus downstream behavioral drivers.
MIF-1 is supplied as a lyophilized, sterile white powder to ensure long-term chemical stability. To preserve peptide integrity prior to reconstitution, solid lyophilized vials should be stored at -20°C or -80°C in a desiccated environment protected from light.
For laboratory reconstitution, researchers should allow the vial to equilibrate to room temperature before adding solvents to prevent condensation accumulation inside the container. MIF-1 displays high aqueous solubility due to its low molecular weight and polar amide C-terminus. Reconstitution can be achieved using sterile target-grade water, phosphate-buffered saline (PBS, pH 7.4), or mild buffer solutions suitable for cell culture media. Once reconstituted into liquid form, aliquots should be used immediately or stored at -80°C to avoid degradation from repeated freeze-thaw cycles.
Because sub-standard reagents introduce unacceptable variables into cellular and neurochemical research, purchasing laboratories must verify analytical purity metrics prior to experimentation. PX1 Research enforces strict quality assurance protocols for every lot of MIF-1 peptide synthesized:
1. Reverse-Phase HPLC: Confirms physical purity exceeding 98.0%, verifying the absence of truncated peptide fragments, deletion sequences, or synthesis side-products. 2. Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact monoisotopic molecular mass (284.36 Da) and sequence fidelity. 3. Endotoxin Assessment: LAL assay verification guarantees endotoxin levels below strictly enforced laboratory thresholds (<0.1 EU/mg), ensuring compatibility with sensitive primary neuronal cell cultures. 4. ISO 17025 Third-Party Verification: Independent analytical validation conducted by accredited US testing facilities.
PX1 Research serves academic institutions, biotechnology organizations, and contract research organizations (CROs) requiring dependable peptide supply chains. Laboratories seeking to scale up experimental models can utilize our bulk procurement programs to obtain uniform, single-lot inventory for large-scale longitudinal trials.
All products are strictly packaged and labeled for in vitro, preclinical, and laboratory research use only. With streamlined online ordering, verified chain-of-custody documentation, and fast fulfillment directly from our domestic US hubs, PX1 Research provides the quality standard required for cutting-edge neuropeptide science.
What is the sequence and molecular weight of MIF-1 peptide?
MIF-1 (Melanocyte-Inhibiting Factor 1) is a synthetic tripeptide with the chemical sequence Pro-Leu-Gly-NH2 (L-prolyl-L-leucyl-glycinamide). It has a molecular weight of 284.36 g/mol.
What primary mechanism does MIF-1 demonstrate in preclinical studies?
Preclinical literature indicates that MIF-1 acts primarily as a positive allosteric modulator (PAM) at dopamine D2 and D3 receptors, enhancing dopamine receptor affinity without altering total receptor density. It also interacts with central mu-opioid signaling networks.
How is the purity of PX1 Research MIF-1 verified?
Every lot of MIF-1 is subjected to Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm >98% purity, ESI-MS mass spectrometry to confirm molecular identity, and LAL testing to quantify endotoxin levels.
What is the recommended storage temperature for lyophilized MIF-1?
Lyophilized MIF-1 powder should be stored at -20°C or -80°C in a dry, dark environment upon arrival. Reconstituted solution aliquots should be frozen at -80°C and protected from multiple freeze-thaw cycles.
What solvents should be used to reconstitute MIF-1 for laboratory assays?
MIF-1 is highly water-soluble and easily dissolves in sterile research-grade water, standard phosphate-buffered saline (PBS, pH 7.4), or physiological buffer solutions suitable for cell culture and tissue prep.
How does MIF-1 differ from the synthetic analog Nemifitide?
Nemifitide is a halogenated synthetic peptidomimetic analog of MIF-1 modified to increase resistance to enzymatic degradation in serum. MIF-1 represents the native, non-modified tripeptide sequence.
Can MIF-1 peptide be ordered for clinical or human use?
No. MIF-1 supplied by PX1 Research is strictly dedicated to laboratory, in vitro, and preclinical research applications. It is not intended for human consumption, therapeutic, or diagnostic procedures.
Where does PX1 Research ship MIF-1 orders from?
All MIF-1 orders are manufactured and dispatched directly from PX1 Research fulfillment facilities located in California and Arizona, with same-day dispatch available for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.